Kyverna Therapeutics, Inc. (KYTX:NASDAQ) closed at $5.39 on October 23, 2026, down 5.93% on the day. The stock trades 60.6% below its 52-week high of $13.67 and 0.6% above its 52-week low of $5.36. Over the past year, it lost 27.6%. Kyverna Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, KYTX closed higher on 130 days (52%). Its best day was December 15, 2025 (+23.23%) and its worst was December 17, 2025 (-32.52%). The stock moved 10% or more in a single session 16 times. It opened at least 5% above the previous day's high 1 time.
Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.
Find more stocks like KYTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.